Abstract | The microenvironment is increasingly recognized to have key roles in cancer, and biomaterials provide a means to engineer microenvironments both in vitro and in vivo to study and manipulate cancer. In vitro cancer models using 3D matrices recapitulate key elements of the tumour microenvironment and have revealed new aspects of cancer biology. Cancer vaccines based on some of the same biomaterials have, in parallel, allowed for the engineering of durable prophylactic and therapeutic anticancer activity in preclinical studies, and some of these vaccines have moved to clinical trials.
. Cancer cells that originate from the same tumour of a patient may also be genetically heterogeneous [4] [5] [6] ; solid tumours tend to have leaky vasculature that allows drug access 7, 8 , but also have elevated interstitial fluid pressure to impede penetration of therapeutics 9, 10 ; and cancer cells can develop drug resistance through multiple mechanisms 11, 12 .
To confront these and additional challenges, many engineering tools and techniques have been created and used both to study cancer in vitro and to develop new anticancer therapeutics. In particular, complex in vitro culturing systems, engineered protein or cell-based diagnostic and therapeutic agents, and sophisticated molecular or cellular delivery devices are in various stages of development. Integration of bioengineering into cancer research and therapy is not only improving the efficacy of traditional cancer treatments such as surgery 13, 14 and chemotherapy 15, 16 , but also advances have transformed biomaterials from being simple structural supports into sophisticated devices that can interact with cells and tissues through well-defined molecular pathways at various size scales to create highly defined microenvironments to direct biological responses. As such, the same materials can now provide both a basis for in vitro mimics of tumours in order to better screen therapeutic approaches and identify new therapeutic targets, and a means to modulate the microenvironment in vivo and direct therapeutic responses against cancerous cells and tumours (FIG. 1) . This Opinion article focuses on two highly interrelated areas in which biomaterials engineering may have a substantial impact on the development of new cancer therapies in the future. The use of biomaterials to engineer 3D human tumours in vitro with defined microenviron ments is first reviewed, as these may both further our understanding of cancer and provide new models for drug screening and identification. We then discuss how biomaterials can be used to manipulate the microenvironment in vivo to alter the immune system, in the context of immunotherapy for cancer.
Biomaterials to create 3D tumour models
One of the most prevalent challenges in cancer research and therapeutic screening is the limitations of current in vitro models 27, 28 , which relate in part to their inability to accurately reflect microenvironmental cues found in vivo. Conventional 2D monolayer models of human cancers have been important tools for studying cancer biology and developing anticancer therapeutics, and they provide a valuable addition to what can be learned using animal models. However, it is becoming increasingly clear that conventional 2D culture models are insufficient to recapitulate many important characteristics of tumours in vivo and are often poorly predictive of drug response in humans [29] [30] [31] . In contrast to 2D monolayer culture models, tumour cells in vivo are supported by a 3D extracellular matrix (ECM) and non-tumour cells, including endothelial cells, immune cells and other stromal cells 1, 32 . Early studies have demonstrated that changing the culture of opening up entirely new modalities of cancer therapy. This Opinion article discusses the current contributions of bioengineering, especially biomaterials engineering, to our understanding of cancer biology and to the development of emerging therapeutic strategies such as cancer immunotherapy. Biomaterial-based delivery systems for chemotherapeutics are now routinely used in the treatment of patients
, but as there have been many excellent reviews on this topic [17] [18] [19] [20] , it will not be reviewed here. Biomaterials, traditionally defined as materials used in medical devices, provide a highly versatile tool to create defined macroand microenvironments, and manipulate cells and tissues in vitro and in vivo. They have been used since antiquity as simple prosthetics to replace damaged tissues 21 , but their degree of sophistication has increased rapidly in recent years. New characterization [22] [23] [24] and synthetic methods 25, 26 , combined with advances in our understanding of biological processes, have greatly extended the variety as well as the size scale at which biomaterials can be designed and synthesized, and have revealed how they specifically affect signal transduction pathways. Together, these cancer cells from 2D to 3D markedly affects cell behaviours, and that 3D cultures often better resemble tumours than conventional 2D monolayers and can improve our understanding of cancer biology 33, 34 . For example, coupled interactions were found between β1 integrin and epidermal growth factor receptor (EGFR) signalling in 3D cultures of malignant human mammary epithelial cells but not in 2D culture 35 . For drug testing, it is important that the cells in the in vitro assay mimic the phenotype within tumours to produce biomedically relevant responses. Although 3D tumour models have not yet had a direct impact on clinical translation, we expect that more sophisticated 3D models will become important tools for anticancer drug discovery and testing in the future. Various 3D culture models have been developed in order to better mimic different aspects of the microenvironment of human cancers. We here discuss biomaterials engineering approaches for modelling the tumour microenvironment, particularly its mechanical and structural functions, and their potential influence on the testing of anticancer drugs (FIG. 2) .
Engineered 3D tumours to better model cancer biology. In order to recapitulate the 3D organization and ECM of tumours, various natural and synthetic materials have been developed to provide architectural support to interacting cells 26, 33 . Natural ECM-derived biomaterials such as collagen, laminin, hyaluronic acid and reconstituted basement membrane (rBM, for example, Matrigel; Corning) were the first and are still the most commonly used materials for 3D culture of cancer cells because of their inherent cytocompatibility, intrinsic cell adhesion properties and ability to be remodelled by cells 33, 36 . However, the batch-to-batch variability, complex molecular composition and uncontrolled degradation of these materials often make it difficult to study the influence of a particular property of the ECM on tumour cells while maintaining other variables unaltered. Synthetic materials such as polyethylene glycol (PEG) and poly(lactide-co-glycolide) (PLG) can provide more precise experimental control over biochemical and mechanical properties in modelling the tumour ECM. However, as these synthetic materials lack natural cell adhesion sites and are not readily remodelled by cells, cell adhesion ligands and biodegradable crosslinkers are often grafted to the polymers. For example, PEG hydrogels containing the integrin-binding polycaprolactone-tricalcium phosphate scaffolds, revealing the paracrine effect of osteoblasts in altering the androgen dependency of prostate cancer cells and supporting their survival 42 . In the context of tumour-immune cell interactions, it has been shown that melanoma cells cultured in 3D models become more resistant to cytotoxic T lymphocytes (CTLs) compared with melanoma cells grown in 2D monolayers, owing to the downregulation of tumour antigens and major histocompatibility complex class I (MHCI), and increased production of lactate 43, 44 . Similarly, 3D culture of lung carcinoma cells diminished their susceptibility to CTL activity. However, this result was attributed to a decrease in heat shock protein 70 (HSP70) expression and associated defective tumour antigen presentation 45 . Glioma spheroids also seemed to have an increased resistance to natural killer (NK) cell cytotoxicity compared with glioma cells grown in 2D monolayers 46 . These findings support the importance of using 3D culture to develop in vitro models of tumour-immune cell interactions. Although the above-mentioned 3D models for studying tumour-immune cell interactions primarily use unsupported tumour spheroids grown in suspension, biomaterial matrices mimicking various tumour microenvironments may also be used to investigate microenviron mental influences in such interactions. For example, porous scaffolds made from chitosan and arginine-glycine-aspartic acid (RGD) peptide and matrix metalloproteinase (MMP)-degradable peptide crosslinkers promoted 3D epithelial morphogenesis of lung adenocarcinoma cells similarly to Matrigel 37 . Another class of biomaterials that is increasingly being used in 3D tumour models is naturally derived polysaccharides such as alginate and chitosan. They are biocompatible and have a broad range of chemical and mechanical properties, but they also lack mammalian cell adhesion sites and often require chemical modification for crosslinking to form gels with desirable physical properties 26 . In addition to providing structural support to cancer cells, 3D matrices are used to create spatially controlled cellular compartments, to allow the interactions between cancer cells and other cells, including immune cells, to be studied in various 3D contexts. For example, collagen-and rBM-based 3D systems have been developed to study tumour-induced angiogenesis by co-culturing various types of cancer cell with human umbilical vein endothelial cells or arterial explants 38, 39 .
Interactions of cancer cells and stromal fibroblasts in three dimensions have also been modelled and investigated using collagen gels 40, 41 . In an in vitro bone metastasis model, prostate cancer cells encapsulated in PEG hydrogels were co-cultured with primary human osteoblasts seeded in bone-mimicking 7, 160, 167 . These nanodrugs have clinically demonstrated higher drug accumulation in tumours and reduced side effects compared with the free drugs 158, [168] [169] [170] . Besides the early generations of nanodrugs, many exciting new nanomaterials and delivery strategies are being investigated in preclinical studies and clinical trials. For example, a higher patient response rate and overall survival have been shown when nanoparticles are used to co-deliver multiple therapeutic agents with precise formulation to tumours compared with conventional administration of drug cocktails 171, 172 . Nanoparticles decorated with ligands that recognize specific receptors of cancer cells 173 , trigger tumour transport mechanisms 174, 175 or camouflage themselves as "markers of self" (REFS 176, 177) can exploit cellular pathways to enhance tumour uptake and avoid immune clearance. Inorganic nanomaterials such as silicon, gold and iron oxide nanoparticles with unique optical or magnetic properties are also being explored for simultaneous drug delivery and tracking [178] [179] [180] [181] . In addition, although not discussed in this Opinion article, it is worth mentioning that biomaterials engineering is also having an impact on cancer diagnostics, offering methods with substantially improved sensitivity and specificity 182, 183 . Nature Reviews | Cancer alginate have been used to study interactions of human prostate cancer cells and lymphocytes. These scaffolds allow immune cell penetration into tumour spheroids to be tracked for a longer period of time in a 3D environment owing to slower scaffold degradation, as compared with collagen or rBM matrices 47 . More sophisticated 3D co-culture models, particularly those incorporating a model of the vasculature, can be fabricated using 3D printing. Sacrificial templates have been printed using glassy carbohydrate or temperature-responsive hydrogels. The templates are embedded within various cell-laden natural and synthetic hydrogels, and can subsequently be dissolved to generate vascular networks in the hydrogels 48, 49 . Various photolithography 50, 51 and soft lithography 52 methods using photocrosslinked materials have also been developed to achieve in vitro mimics of 3D vascularized tissues. These sophisticated architectures have not yet been widely applied as 3D tumour models, but are likely to provide important tools for studying various aspects of cancer biology in the future.
As tumours have distinct mechanics compared with normal tissues, biomaterials have also been utilized in 3D culture to model the mechanical properties of the tumour microenvironment, and to study the effects of ECM mechanics on tumour development and progression. Mechanical cues regulate various cell behaviours through mechanotransduction, including proliferation, migration models were developed using methacrylatemodified hyaluronic acid hydrogels with different mechanical properties. These hydrogels can mimic a range of stiffness that encompasses normal and tumorigenic brain tissues, enabling the study of cancer cell invasion into different matrices 59 . Synthetic hydrogels based on PEG have been used in lung adenocarcinoma models to study the influence of matrix stiffness on the epithelial-mesenchymal transition. The PEG hydrogels were modular and had higher stiffness compared with collagen or rBM matrices 37 . Although the importance of ECM mechanics is increasingly recognized, the majority of the studies have focused on the elasticity (stiffness) of the ECM, but overlooked the potential role of its viscoelasticity (both viscous and elastic characteristics). A recent study showed that viscoelastic substrates could stimulate the spreading of osteosarcoma cells to a greater extent than purely elastic substrates with the same initial elastic modulus 60 . Future 3D models using materials developed to mimic the viscoelasticity of various tumour niches will potentially help to better dissect the function of ECM mechanics in tumour progression.
Engineered 3D matrices have also been developed to recapitulate the spatiotemporal complexity of soluble factors (for example, oxygen and growth factor gradients) found in tumours, and to study their contribution to tumour growth. Conventional 2D culture in reduced oxygen environments has helped to improve our understanding of the role of hypoxia, but does not recapitulate the spatial variation of oxygen in tumours. The use of stacked layers of chromatography paper infused with suspensions of cancer cells in Matrigel was shown to generate defined oxygen gradients in the 3D culture; necrotic cells as well as overexpression of vascular endothelial growth factor (VEGF) and insulin-like growth factor binding protein 3 (IGFBP3) were observed at the hypoxic core of the 3D culture 61 . Alginate hydrogels have also been used to modulate oxygen concentration. This 3D system was able to model various uniform or gradient hypoxic conditions by controlling the hydrogel spatial configuration, which allowed studies of the secretion of pro-angiogenic factors (VEGF and interleukin-8 (IL-8)) from cancer cells in response to ECM cues such as integrin-matrix engagement under different hypoxic conditions 62, 63 . To control the spatiotemporal availability of growth factors in a 3D tumour model, and differentiation [53] [54] [55] . In the context of cancer, tumour cells remodel the ECM and change its mechanical properties, and, in turn, the altered mechanical niche is likely to influence tumour progression 32 . For example, breast cancer stroma is stiffer than normal stroma owing to increased collagen deposition and ECM crosslinking. Using 3D in vitro models fabricated from rBM and collagen, it was discovered that high matrix stiffness together with increased collagen concentration or crosslinking induced a malignant phenotype in normal mammary epithelium 56, 57 . To understand the specific role of increased matrix stiffness in this transformation independently of changes in matrix composition and architecture, an interpenetrating polymer network (IPN) of rBM and alginate matrix was developed 58 . The stiffness of these IPNs can be modulated by simply controlling the ionic crosslinking of alginate without changing the polymer concentration, cell-adhesion-ligand density or the pore size of the matrix. Using this IPN model, it was found that the increased matrix stiffness was sensed through β4 integrin, RHO family GTPase RAC1 and the PI3K pathway, leading to loss of apicobasal polarity, cell invasion into the basement membrane, increased proliferation and other hallmarks of a malignant phenotype in mammary epithelium 58 . Other biomaterials have also been used to model the mechanical properties of various tumours. As hyaluronic acid is a major component of brain ECM, 3D glioblastoma controlled drug delivery technologies have been exploited. For example, a hyaluronic acid hydrogel bilayer system was developed to study the function of heparin-binding EGF-like growth factor (HB-EGF) in the growth of prostate cancer spheroids. As HB-EGF is found in prostate stroma and bound to ECM, HB-EGF was encapsulated in microparticles to control its availability. Sustained release of HB-EGF from microparticles embedded in the top layer of the hydrogel promoted the growth of tumour spheroids in the bottom layer, and increased VEGF and IL-8 expression in the cancer cells 64 . Methods using microfluidics 65 and photopatterning 66 may be useful in achieving more precise spatiotemporal control of soluble factors in 3D culture models by controlling the flow of fluids containing the factors, and photo-induced coupling or cleavage of factors, respectively. These approaches are also likely to be useful in the study of tumour cell responses to spatio temporally controlled cytokines in the context of immunotherapy.
Engineered in vitro models for testing anticancer therapeutics. As it is desired to better mimic human biology and dismiss potentially ineffective or unacceptably toxic therapeutic candidates as early as possible, 3D in vitro human tumour models are increasingly being explored for evaluation of new therapies 67 . Although 2D cell culture models have been an invaluable tool in identifying potential anticancer agents at the early stages of drug discovery, they provide little information on drug responses influenced by tumour heterogeneity and the microenvironment. By contrast, simple tumour spheroid models have shown drug responses that are more similar to those of tumours in vivo compared with 2D models, and are increasingly being used to evaluate anticancer agents under 3D conditions [68] [69] [70] . For example, 3D tumour spheroids created using hanging drop methods have been commercialized by companies such as 3D Biomatrix and InSphero, and are being explored for high-throughput drug screening by pharmaceutical companies. To integrate additional influences of the tumour microenvironment, collagen gels containing heterospheroids of liver carcinoma cells and fibroblasts were used to study changes in drug resistance and metabolism associated with culture dimensionality, stromal cells and the ECM. This study found that suspended 3D heterospheroids had higher drug resistance than 2D monolayers or suspended homospheroids containing only cancer chitosan-alginate scaffolds was used to evaluate CTL function in the presence or absence of tumour-associated fibroblasts. It was found that fibroblasts decreased tumour necrosis factor (TNF) secretion by CTLs, probably owing to elevated production of IL-10 and transforming growth factor-β (TGFβ) in the co-culture 75 .
In another study, drug inhibition of tumour cell-macrophage paracrine interactions was analysed using co-culture of breast adenocarcinoma cells and macrophages in alginate hydrogel fibres. Gefitinib, an EGFR inhibitor, and a RAC1 inhibitor were both able to impair macrophage migration to cancer cells, and the 3D cell distribution and cancer cell/macrophage ratio affected drug responses 76 . Although generally faster than in vivo models, 3D tumour models for drug testing typically require increased processing time relative to 2D cell monolayers. In order to address this problem, automated techniques such as microfluidics have been used to achieve high-throughput compound screening in 3D tumour models. For example, a micro fluidic-based platform has been developed to fabricate 'microtissues' that can encapsulate the desired combination of cancer cells, stromal cells and ECM components. These 3D microtissues allow cancer cell responses to various microenvironmental cues to be investigated as the specific matrices, soluble factors and stromal cells are changed, and enable drug candidates to be tested 77 . Engineered 3D tumour models may also potentially help to improve animal models for drug development. Xenograft animal models are typically established by cells, and placing either type of spheroid in a collagen matrix further increased drug resistance 71 . A 3D model of Ewing sarcoma has also been developed using biodegradable, highly porous polycaprolactone scaffolds fabricated by electrospinning. This 3D culture model showed closer resemblance to xenograft tumours in phenotype and drug resistance compared with a 2D monolayer model. In addition, cancer cells in the 3D system had a slower proliferation rate and better mimicked in vivo tumour growth, which allowed investigation of the long-term impact of drug exposure 72 . Although patient-derived xenograft (PDX) cancer models have been established by engrafting and maintaining patient-derived tumour tissues in immunocompromised animals 73 , the complexity of these models and long latency following engraftment have slowed their broad adoption. To circumvent these and other potential problems (for example, drift of PDX stromal components from human to host species), patient-derived prostate xenograft tumour cells were cultured in hyaluronic acid-based hydrogels to mimic the microenvironment of bone metastases in prostate cancer. This 3D system was shown to maintain the native androgen receptor expression of the cancer cells, and higher docetaxel resistance was observed with patient-derived cells than in a commonly used prostate cancer cell line, although the relevance to patient drug response still needs to be verified 74 .
In vitro 3D models to test immunotherapies are also being developed. For example, a 3D model of mouse mammary carcinoma cells cultured in porous inoculation of cancer cells previously cultured on stiff 2D substrates. However, culture conditions can substantially alter cell gene expression and phenotype 78 , and certain effects may persist for a long period of time even after conditions have been altered 73, 79, 80 . For example, soft fibrin gels were shown to promote growth and possibly 'priming' of stem-cell-like cancer cells in 3D culture, and enhance their ability to form tumours in mice 81 . Similarly, culture in PLG or chitosan-alginate 3D matrices enhanced the subsequent ability of cancer cells to grow tumours and promote angiogenesis in mice, compared with cells from 2D culture 82, 83 . Although still in a very early stage, further development and evaluation of these approaches may potentially help to create xenograft animal models that can better recapitulate the phenotypes of actual human tumours for drug testing.
Future directions and considerations.
As 3D cancer models are still in the early stages of development, several issues still remain to be addressed. First, factors such as specific disease relevance and processing efficiency will need to be evaluated and optimized in large-scale studies in order to fully establish and exploit 3D tumour
Biomaterials in cancer immunotherapy
Harnessing the immune system to treat cancer has been a goal in medicine for more than a century, driven by the potential to provide specific, durable and adaptive reactivity towards tumours 87, 88 . Recently, the benefit and efficacy of certain cancer immunotherapies, including checkpoint blockade antibodies, were successfully established in large clinical trials [89] [90] [91] [92] , and adoptive cell transfer (ACT) is also extremely promising 93, 94 . Biomaterials may enhance the efficacy of many of these new therapies or other immunotherapies (for example, cancer vaccines) via control over the microenvironment in which immune cells encounter antigens, stimulatory signals, cancerous cells or other immunomodu latory cells (FIG. 3) . Therapeutic viral particles can also be considered biomaterials, but are not covered here as they are typically not intended to directly alter the microenviron mental conditions of immune cells and have been discussed in previous reviews 95 .
Biomaterial-based cancer vaccines.
Therapeutic cancer vaccines aim to generate immune reactivity against existing tumours in the host. Through vaccination, antigen-presenting cells (APCs) such as dendritic cells (DCs) are activated to elicit tumour-specific CTLs 87 . The activation of APCs can be achieved either ex vivo or in vivo. Sipuleucel-T (Provenge; Dendreon), the first cell-based therapeutic cancer vaccine to be approved by the US Food and Drug Administration (FDA), demonstrated the potential of adaptive immunity in combating cancer, but the complexity of the treatment (for example, ex vivo cell manipulation and transport of living cells between clinic and production facility), and its associated high cost hampered its uptake in the clinical setting 96 . In contrast, cancer vaccines based on peptides, viruses or DNA encoding tumour antigens historically have shown low overall objective response rates in clinical trials 97, 98 , perhaps because of inappropriate temporal or spatial control over antigen presentation and immune cell activation, and a limited ability to overcome the immunosuppressive mechanisms of tumours. To generate tumour-specific CTLs, it is crucial to activate APCs in a stimulatory microenvironment that induces antigen-specific immunity rather than tolerance 99, 100 . The kinetics of antigen exposure are also important, as too short a time of a low dose or too long a time of a high dose of antigen exposure, at least models for drug discovery and screening. To date, few, if any, of the discoveries made in 3D cancer models have been validated in cancer patients. This calls for closer collaborations between researchers, physicians and the pharmaceutical industry. Also looking forward, there is substantial potential for advanced microfluidic 3D cell culture devices that more closely mimic the physiological function of human organs (organs-on-chips) in drug screening than static 3D model systems 84 . A 'human-body-on-a-chip' that combines several different, fluidically linked organs-on-chips 85 is a particularly appealing concept for testing new anticancer therapeutics including immunotherapies, as it could provide a human test bed that encompasses the dynamic, multiple cellular interactions required to mount an effective immune response to cancer. This approach may also potentially provide an in vitro platform for personalized therapy evaluation by using cells or tissues directly from patients 86 . However, the potential benefits of all 3D human cancer models must be balanced with the increased complexity and difficulty of performing large-scale discovery science or drug screening, compared with the classic 2D systems.
Glossary

Adjuvants
Substances that modify the immune responses to an antigen.
Bolus vaccination
Injection of vaccine components suspended in solution.
Cellular immune responses
Responses that involve the activation of phagocytes and antigen-specific cytotoxic T lymphocytes in response to an antigen.
Elastic modulus
A measure of a substance's resistance to being deformed elastically under force, as calculated by the ratio of applied stress to the resulting strain in the substance.
Elasticity
The ability of solid materials to return to their original shape after being deformed.
Electrospinning
An approach to the fabrication of nano-or microscale fibres through electrostatic repulsion-induced formation of a jet of a polymer solution.
Humoral immune responses
Used here to indicate responses that involve the activation of B cells to secrete antibodies to a specific antigen.
Interpenetrating polymer network
(IPN). A polymer comprising two or more networks that are interlaced on a molecular scale but not covalently bonded to each other.
Microfluidics
Technology that processes or manipulates small volumes of fluids using channels with dimensions of tens to hundreds of micrometres.
Photolithography
The process of transferring patterns onto a substrate using light and light-sensitive chemicals.
Pluronic copolymer
A block copolymer of polyethylene glycol and polypropylene glycol.
Sacrificial templates
Templates fabricated using materials that can be removed later to form desired void structures inside a scaffold.
Soft lithography
A technique for fabricating or replicating structures using elastomeric stamps or moulds.
Virus-like particle
(VLP). A protein structure that mimics the organization of a virus but lacks the viral genome.
Viscoelasticity
A property of materials that exhibit both viscous and elastic characteristics when undergoing deformation. Viscoelastic materials can flow under forces, but exhibit some elastic behaviour. . Specifically, the macroporous PLG vaccine system has a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF), which promotes DC accumulation at the vaccine scaffold. The vaccine is loaded with tumour lysate as an antigen source and also presents nanoparticles of CpG oligodeoxynucleotides (or CpG for short), which are agonists of Toll-like receptor 9 (TLR9) and serve as a 'danger signal' for DC activation. The activated and antigen-loaded DCs subsequently migrate to lymph nodes 105 . This vaccine leads to a strong CTL response against established melanoma (syngeneic B16-F10 model), causing complete regression of tumours in ~47% of mice in preclinical studies 106 . A human version of this vaccine (called WDVAX) is currently in a Phase I clinical trial for stage IV melanoma 107 . Importantly, this type of biomaterial design for a cancer vaccine is modular, and various immuno stimulatory agents can be incorporated. For example, inflammatory cytokines such as chemokine (C-C motif) ligand 20 (CCL20) or FMS-related tyrosine kinase 3 ligand (FLT3LG) can be used in place of GM-CSF in the vaccine to alter DC subset recruitment and activation, and these also generate antitumour responses in a preclinical melanoma model 108 . Alteration of the source of tumour lysate used as the antigen allows the PLG vaccine system to demonstrate therapeutic activity in mouse lung carcinoma and rat glioma models 109, 110 . Local immunogenic niches that control immune cell trafficking and activation have also been created using other materials such as gelatin, alginate hydrogels and or intramuscularly -in a size range of 10-100 nm are optimal for lymph node targeting through lymphatic drainage 102, 116, 117 . Small (25 nm) pluronic copolymer-coated nanoparticles that were intradermally injected were efficiently transported to draining lymph nodes through interstitial flow and retained for at least 120 h. The nanoparticles were readily internalized by DCs and macrophages in the lymph nodes. By comparison, 100 nm nanoparticles seemed to be only ~10% as efficient. When used to deliver the model antigen ovalbumin (OVA), the 25 nm nanoparticles also induced higher humoral immune responses compared with 100 nm nanoparticles 116 . A study using another type of nanoparticle (inert polystyrene beads) showed that 40 nm was optimal for targeting DCs in the lymph nodes and generating antitumour immunity in an OVA-expressing mouse lymphoma model (EG7-OVA) 118 .
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Besides exploiting size-dependent targeting to the lymph nodes, biomaterialbased vaccines have also used binding ligands of DC receptors or hitchhiked natural transportation mechanisms in the body to actively target DCs. For example, both inorganic and polymeric nanoparticles mesoporous silica micro-rods [111] [112] [113] [114] . As these materials are either highly deformable or self-organizing, they can be administered by injection, instead of the surgical implantation required for WDVAX. Many of the scaffold vaccine systems use tumour lysates or irradiated tumour cells as the antigen source. This design can create personalized vaccines to address tumour heterogeneity and potentially hit multiple tumour antigens simultaneously. However, this approach may also lead to increased complexity in clinical translation, compared with using defined antigens. One alternative approach that could be pursued in the future is to use synthetic neoantigens identified by exome sequencing of cancer cells from individual patients 115 . Biomaterials, because their sizes are tunable at the nanoscale level, can also be transported to lymph nodes, where they alter the microenvironment of the targeted immune cells. As large numbers of DCs reside in the secondary lymphoid organs, delivery of vaccines to lymph nodes is an attractive alternative to recruiting the migratory DCs to a vaccination site. It has been shown that, depending on the type of material and animal model, interstitial particles -administered subcutaneously have shown enhanced binding and uptake by DCs when coupled with antibodies against CD40 or DEC-205 (also known as CD205 or LY75) receptors [119] [120] [121] [122] . A recent study 123 exploited the clinical finding that injected dyes that bind avidly to endogenous albumin were efficiently transported to lymph nodes and filtered by resident APCs 124, 125 . Inspired by this 'albumin hitchhiking' , amphiphilic macromolecules were developed to deliver peptide antigens to lymph nodes. The structure comprised a peptide antigen linked to a lipophilic albumin-binding tail, with a hydrophilic PEG polymer chain as the linker to improve solubility. When injected subcutaneously into mice, these amphiphilic macromolecules were efficiently transported with endogenous albumin to lymph nodes, targeting DCs and macrophages. Vaccination with the amphiphilic peptide antigens and CpG adjuvant significantly increased antigen-specific CTL expansion and therapeutic efficacy against established tumours (B16-F10 melanoma) compared with unmodified peptide and CpG immunizations 123 . Recent studies have shown that targeting tumour-draining lymph nodes specifically with nanoparticle-based cancer vaccines or adjuvants induced stronger cellular immune responses compared with targeting uninvolved lymph nodes, possibly owing to alteration of the immunosuppressive environment of tumour-draining lymph nodes to a more stimulatory condition and to high exposure of immune cells in these lymph nodes to tumour-associated antigens 126, 127 . An interesting direction for future studies would be to combine the aforementioned APC-targeting strategies to home in on specific immune cells in the tumour-draining lymph nodes 128 . Biomaterials engineering in adoptive cell transfer. T cell-based ACT, including tumour-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, has become one of the most successful developments in cancer immunotherapy 93, 94, 146 . However, these promising treatments have some notable challenges, including expansion of T cells and maintenance of their effector function, both during ex vivo cell production and in vivo after transplantation.
Biomaterials may address many of the challenges facing T cell-based ACT by providing a means to locally and specifically provide stimulatory cues. First, these therapies typically require large numbers of autologous tumour-specific T cells, but T cells collected directly from the peripheral blood or tissues of patients are normally low in number and can be hyporesponsive 147 .
To activate and expand the cells ex vivo, microparticles coated with CD3-specific and CD28-specific antibodies have been developed as 'artificial APCs' to provide primary and co-stimulatory signals. These macroparticles also contain superparamagnetic iron oxide so that they can be easily separated from cells by a magnetic field. This method has now become a common tool in immunology and is widely used in CAR T cell clinical studies 148 . More recently, it was reported that biodegradable antigen into the cytosol, promoting crosspresentation of antigen [130] [131] [132] [133] . In addition, co-delivery of antigen and TLR agonists simultaneously to APCs can promote CD8 + T cell responses. For example, multilamellar lipid nanoparticles have been loaded with a model antigen together with the TLR4 agonist monophosphoryl lipid A (MPLA). These nanoparticles consist of multiple concentric lipid bilayers that are crosslinked within the vesicle walls to stably retain antigen and MPLA. The nanoparticles elicited a high percentage of antigen-specific CD8 + T cells in the peripheral blood of mice after a priming injection and two boosters, and this response was dependent on co-delivery of the stably incorporated TLR agonist 134 . Similarly, enhanced cellular immunity against melanoma (B16-F10) was also observed using other nanomaterial carriers when a melanoma antigen (tyrosinase-related protein 2 (also known as l-dopachrome tautomerase) peptide) and various TLR agonists were co-delivered 135, 136 . Interestingly, preclinical studies have shown that combined stimulation of multiple TLRs or NOD-like receptors (NLRs) may have a synergistic effect and enhance vaccine efficacy [137] [138] [139] . A recent melanoma clinical trial using a virus-like particle (VLP) vaccine containing CpG and the melan-A peptide antigen, given together with incomplete Freund's adjuvant injection and imiquimod topical cream (a TLR7 agonist), significantly increased memory and effector CD8 + T cell responses compared with the vaccine alone 140 . This suggests that incorporating multiple TLR agonists simultaneously into nanoparticle-based cancer vaccines may also potentially improve the efficacy of therapeutic vaccines in humans.
Certain materials have intrinsic adjuvancy or the capacity to create an inflammatory microenvironment, which can be exploited in the design of cancer vaccines. Aluminium salts (alum), the mechanism of which is not yet fully understood, were until recently the only type of adjuvant approved for human vaccination 141 . Silica particles were recently shown to activate the innate immune response and promote cellular immunity, possibly through inflammasome activation of APCs 113, 142 . ISCOMATRIX (CSL) adjuvant consists of cage-like nanoparticles comprising saponin, cholesterol and phospholipid. It does not seem to activate TLRs, but it induces an innate immune response by inflammasomedependent and -independent IL-18 production, possibly owing to endosomal stress and cell damage 143 . Vaccination with PLG microparticles containing an additional signal, the T cell growth factor IL-2, further enhanced T cell expansion, especially of CD8 + T cells. The sustained release of IL-2 from microparticles in the vicinity of T cell contacts, in a paracrine fashion, seemed to be more effective than simply adding soluble IL-2 to the culture medium 149 . Besides biochemical factors, physical characteristics, such as the shape and size, of the microparticles also affect their T cell expansion efficiency 150 . For example, ellipsoidal PLG microparticles showed enhanced CD8 + T cell expansion activity compared with spherical microparticles with the same volume and protein content, possibly as a result of increased interaction of T cells with the long axis of the ellipsoidal microparticles 151 . Biomaterials may also enable us to prevent the decline in viability and function of the transplanted cells in ACT by creating optimal cytokine presentation in the cellular microenvironment. To improve the persistence of the transplanted T cells, systemic administration of cytokines (for example, IL-2 or IL-15) is often used 146, 152 . However, high-dose systemic cytokines can cause severe side effects owing to their broad range of activities 153 . Instead, the function of transplanted T cells can be enhanced by conjugating cytokine-loaded nanoparticles to the surface of the transplanted cells 154 . Stable attachment to the cells for at least 4 days can be achieved by covalent conjugation of liposomal nanoparticles to the surface thiols on T cells. In a B16-F10 melanoma model, transplanted CTLs conjugated with nanoparticles that release the cytokines IL-15 superagonist and IL-21 demonstrated a marked improvement in tumour elimination compared with CTLs with systemic co-injection of the free cytokines 154 . Nanoparticles conjugated to the T cell surface can also be used to deliver small molecular inhibitors (for example, an inhibitor of the protein tyrosine phosphatases SHP1 (also known as PTPN6) and SHP2 (also known as PTPN11), which normally downregulate T cell receptor activation) into the T cell synapse, achieving a greater adoptive T cell expansion at the tumour site 155 . However, one caveat of such approaches is that the cell-bound nanoparticles will be diluted during T cell expansion in the body, limiting the duration of stimulation from the nanoparticles. A possible solution is to target transplanted T cells in vivo using nanoparticles coupled with ligands specific to these cells 156 . Alternatively, a recent study used a porous alginate scaffold, and between the two areas is expected to be rapid and fruitful. This will allow, for example, discoveries on one type of cancer to be quickly applied to another. Also, when the role of specific signals (for example, local cytokine gradients) in regulating immune cell activation is identified in 3D in vitro systems, these findings could be recapitulated in vivo using the same or a similar material system for therapeutic purposes. Conversely, new understanding of complex immune responses, often involving multiple cell types, that result from therapeutic use of biomaterials will then feed back into the design of new 3D in vitro models. Overall, the addition of biomaterials engineering to cancer research and therapies contributes to an exciting time in the search for better cancer therapies. similar to those used in 3D in vitro cancer models 47, 63 , to expand and deliver CTLs in situ by implanting a CTL-loaded scaffold adjacent to tumours or at resection sites. Microspheres containing IL-15 superagonist and CD3-specific, CD28-specific and CD137-specific antibodies were also incorporated into the scaffold to provide a stimulatory microenvironment to the loaded CTLs 157 .
Future directions and considerations.
Biomaterial-based cancer vaccines are expected to complement and synergize with the checkpoint blockade and ACT therapies that are rapidly moving to the front line of cancer treatment. This combination would address two key factors for effective immunotherapy: the generation of robust tumour-specific CTLs and the inhibition of tumour-induced immunosuppression. Personalized cancer vaccines are also an important direction because of the heterogeneity of tumours between patients, especially from the immunotherapy standpoint. Incorporation of patientspecific neoantigens identified by genetic profiling may enhance the efficacy of biomaterial-based cancer vaccines 115 . However, clinical adaptation of biomaterial-based immunotherapies will require the pharmaceutical industry to incorporate a much greater emphasis on materials science and engineering than has been typical in the past. This includes the new approaches required to manufacture this type of therapy in contrast to small-molecule drugs and biologics, and altered regulatory and approval pathways relating to the resultant combinations of materials and drugs. The recent manufacturing difficulties for Doxil (Janssen; liposomal doxorubicin) point to the challenges that can arise from material-drug combinations 158 .
Conclusions
The ability of biomaterials to create defined microenvironments is expected to have a major impact on both the discovery and clinical translation processes in cancer, and to increase exponentially in the coming years. In many areas of cancer research 3D in vitro models that better recapitulate in vivo tumour biology are beginning to replace 2D models. The first personalized biomaterialbased cancer immunotherapy (WDVAX) has recently moved to a clinical trial 159 . The frequent use of the same polymers, and even scaffold architectures, in these two developing areas suggest that transfer of knowledge and technologies both within
